MedinCell Gets ISS ESG Prime Rating for Strong CSR
Image courtesy of blog.submittable.com
Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.
The rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector.
ISS, one of the world’s leading rating agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.
MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders.
The first product based on Medincell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipeline of other products follows.
For more investor-related news